NEPHRIX Biosolutions, the kidney disease preclinical research CRO
As a dedicated CKD CRO, NEPHRIX Biosolutions operates all core R&D activities (animal studies, cell culture, molecular biology, and biochemistry) in independent, secured, dedicated laboratory space. For advanced histology imaging, NEPHRIX Biosolutions has access to specialized platforms at Université Paul Sabatier (Toulouse III), extending its capacity for high-resolution tissue analysis without compromising data confidentiality or study independence.
Whether you are developing a new therapeutic candidate for fibrosis, inflammation, Diabetic Kidney Disease (DKD), or Acute Kidney Injury (AKI) progressing toward CKD, our team delivers the preclinical data packages you need to advance your program with confidence.
What’s behind every study at NEPHRIX Biosolutions?
Every study is run within a controlled, purpose-built environment designed for reproducibility and regulatory-grade rigor:
- Scientifically validated kidney models (in vitro and in vivo) covering CKD, DKD, and AKI
- Experienced renal biologists with hands-on model expertise
- Standardized, reproducible protocols aligned with regulatory expectations
- Integrated histology, biomarker, and molecular biology readouts
Integrated Preclinical CRO Infrastructure
NEPHRIX Biosolutions operates within PROLOGUE BIOTECH, a biotech business incubator. All R&D activities are performed in independent, dedicated areas with secured access. Our facilities include:
- SPF animal housing facility (200 m²): quarantine + functional evaluation areas
- Cell culture laboratories
- Molecular biology and biochemistry laboratories
- CellInsight CX7 high-content imaging platform
- Histology platform
- Biospecimen storage (-80°C, -150°C, liquid nitrogen)
- Secured data archives
Frequently Asked Questions - Kidney Preclinical Research Services
We run a full panel of validated rodent CKD models including UUO, adenine diet, STZ-induced diabetic nephropathy, IRI, IgA nephropathy, and cisplatin-induced AKI. All models are supported by histological, biochemical, and molecular biology endpoints.
Yes. We work with sponsors from study design through final report, adapting endpoints and readouts to your compound’s mechanism of action and regulatory requirements.
We work primarily with rats and mice. Model and strain selection is made collaboratively based on the disease indication and scientific rationale.
Yes, our integrated biomarker services cover plasma and urinary markers of kidney function and injury (creatinine, BUN, KIM-1, NGAL, and others), alongside histological scoring and gene expression analysis.